Effects of Curcumin on Improving Mild Cognitive Impairment in Adults and Elderly Subjects with Metabolic Syndrome: A Randomized Controlled Trial

Phase 4

• Conditions: Metabolic syndrome patients with mild cognitive impairment; metabolic syndrome; mild cognitive impairment; cognitive dysfunction; mild neurocognitive disorder

• Registration Number: TCTR20210304001
• Lead Sponsor: Faculty of Medicine, Chiang Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-04
• Study Completion: 2022-12-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Metabolic syndrome patients with mild cognitive impairment
Age 45-75 years old

Exclusion Criteria

1. Prior diagnosis of dementia or positive screening for dementia
2. Having depression
3. Recent infected or anti-biotic use within 4 weeks
4. Recent surgery less than 3 months
5. Chronic kidney disease stage 4 and 5
6. Having cancer with active treatment or autoimmune disease
7. Allergy to curcumin
8. Abnormal liver function test

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cognitive performance at 6 months MONTREAL COGNITIVE ASSESSMENT (MoCA) test

Secondary Outcome Measures

Name	Time	Method
Biomarkers at 6 months Changes in biomarkers, inflammatory proteins, and oxidative stress indicator